(Q68686231)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2291880%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

title

Debrisoquine oxidation phenotype and susceptibility to lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2291880%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

1 reference

1 reference

A R Boobis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2291880%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

D S Davies

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2291880%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

language of work or name

English

0 references

publication date

1 October 1990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2291880%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Clinical Pharmacology

26 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2291880%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2291880%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2291880%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

page(s)

653-656

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2291880%20AND%20SRC:MED&resulttype=core&format=json

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine

26 September 2019

cites work

1 reference

12 December 2020

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin

1 reference

12 December 2020

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects

1 reference

12 December 2020

Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.

1 reference

12 December 2020

Diurnal effects on debrisoquine hydroxylation phenotyping

1 reference

12 December 2020

Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype

1 reference

12 December 2020

Debrisoquine metabolism and genetic predisposition to lung cancer

1 reference

12 December 2020

The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk

1 reference

12 December 2020

Debrisoquine oxidation phenotype and susceptibility to lung cancer

1 reference

12 December 2020

Genetic predisposition to lung cancer

1 reference

12 December 2020

The rationale for case-control methodology in epidemiological studies of cancer risk (response to Speirs et al., 1990)

1 reference

12 December 2020

Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers

1 reference

12 December 2020

The disposition of debrisoquine in hypertensive patients

1 reference

12 December 2020

Hypotensive response to debrisoquine and hydroxylation phenotype

1 reference

12 December 2020

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 reference

12 December 2020

Metabolic oxidation phenotypes as markers for susceptibility to lung cancer

1 reference

12 December 2020

10.1111/J.1365-2125.1990.TB03832.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2291880%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2291880%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

1 reference